Oral immunotherapy combined with omalizumab for high–risk cow’s milk allergy: a randomized controlled trial

We evaluated the efficacy and safety of oral immunotherapy (OIT) combined with 24 weeks of omalizumab (OMB) at inducing desensitization in children with cow’s milk allergy (CM) compared with an untreated group. The present study was a prospective randomized controlled trial. Sixteen patients (age, 6...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2017-12, Vol.7 (1), p.17453-10, Article 17453
Main Authors: Takahashi, Masaya, Soejima, Kazuhiko, Taniuchi, Shoichiro, Hatano, Yasuko, Yamanouchi, Sohsaku, Ishikawa, Hideki, Irahara, Makoto, Sasaki, Youhei, Kido, Hiroshi, Kaneko, Kazunari
Format: Article
Language:English
Subjects:
14/35
631/250/21/2498
631/250/251/1574
Allergies
Children
Clinical trials
Cow's milk
Food allergies
Humanities and Social Sciences
Immunoglobulin E
Immunotherapy
Milk
Monoclonal antibodies
multidisciplinary
Science
Science (multidisciplinary)
Skin tests
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the efficacy and safety of oral immunotherapy (OIT) combined with 24 weeks of omalizumab (OMB) at inducing desensitization in children with cow’s milk allergy (CM) compared with an untreated group. The present study was a prospective randomized controlled trial. Sixteen patients (age, 6–14 years) with high IgE levels to CM were enrolled in the present study. Patients were randomized 1:1 to receive OMB-OIT group or untreated group. The primary outcome was the induction of desensitization at 8 weeks after OMB was discontinued in OMB-OIT treated group and at 32 weeks after study entry. None of the 6 children in the untreated group developed desensitization to CM while all of the 10 children in the OIT-OMB treated group achieved desensitization (P 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-017-16730-6